Propylhexedrine

Propylhexedrine

SCHEMBL4900116

CNC(C)CC1CCCCC1.Cl

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Propylhexedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
SIGMAR1 known ✓ Q99720 1/20 0.36
CTSK P43235 6/20 0.41
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CTSL P07711 3/20 0.34
CTSB P07858 3/20 0.34
CTSH P09668 2/20 0.34
LTA4H P09960 1/20 0.34
METAP2 P50579 1/20 0.33
CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Levopropylhexedrine SCHEMBL20780004 0.98 CTSK (0.42) CTSKMEN1KMT2ASIGMAR1CTSL
Propylhexedrine SCHEMBL28537 0.98 CTSK (0.42) CTSKMEN1KMT2ASIGMAR1CTSL
Cyclopentamine SCHEMBL317336 0.98 CTSK (0.39) CTSKMEN1KMT2ASIGMAR1CTSL
Levopropylhexedrine SCHEMBL161851 0.98 CTSK (0.42) CTSKMEN1KMT2ASIGMAR1CTSL
Propylhexedrine SCHEMBL28890426 0.95 CTSK (0.41) CTSKMEN1KMT2ASIGMAR1CTSL
Cyclopentamine SCHEMBL13479599 0.95 CTSK (0.40) CTSKMEN1KMT2ASIGMAR1CTSL
Cyclopentamine SCHEMBL249708 0.95 CTSK (0.40) CTSKMEN1KMT2ASIGMAR1CTSL
SCHEMBL27308544 0.91
SCHEMBL22627190 0.79 CTSK (0.32) CTSK
SCHEMBL23241391 0.77 OPRK1 (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456318-B2 Process for preparing benzylated amines MALLINCKRODT INC. (US) 2008-11-25 US claimed
US-20080188685-A1 Process for Preparing Benzylated Amines MALLINCKRODT INC. (US) 2008-08-07 US claimed
CN-101098848-A Process for preparing benzylated amines MALLINCKRODT INC (US) 2008-01-02 CN claimed
EP-1838658-A1 PROCESS FOR PREPARING BENZYLATED AMINES MALLINCKRODT, INC. (US) 2007-10-03 EP claimed
WO-2006073547-A1 PROCESS FOR PREPARING BENZYLATED AMINES MALLINCKRODT INC. (US) 2006-07-13 WO claimed
US-6375461-B1 Gingival retraction cords incorporating propylhexedrine ULTRADENT PRODUCTS, INC. 2002-04-23 US claimed
EP-1188419-A2 Gingival retraction cords Ultradent Products, Inc. (US) 2002-03-20 EP claimed
US-6309221-B1 A KIT INCLUDING PROPYLHEXEDRINE AND AT LEAST ONE IN-SITU POLYMERIZABLE MONOMER (PREFERABLY A PHOPHOALKYL ESTER OF METHACRYLIC ACID) CAPABLE OF ADHERING TO DENTIN AND BECOMING A BARRIER TO MICROORGANISMS ULTRADENT PRODUCTS, INC. 2001-10-30 US claimed
US-7456318-B2 Process for preparing benzylated amines MALLINCKRODT INC. (US) 2008-11-25 US disclosed
US-20080188685-A1 Process for Preparing Benzylated Amines MALLINCKRODT INC. (US) 2008-08-07 US disclosed
CN-101098848-A Process for preparing benzylated amines MALLINCKRODT INC (US) 2008-01-02 CN disclosed
EP-1838658-A1 PROCESS FOR PREPARING BENZYLATED AMINES MALLINCKRODT, INC. (US) 2007-10-03 EP disclosed
US-20070129444-A1 Novel weight reduction composition and uses thereof MALLINCKRODT INC. 2007-06-07 US disclosed
WO-2006073547-A1 PROCESS FOR PREPARING BENZYLATED AMINES MALLINCKRODT INC. (US) 2006-07-13 WO disclosed
EP-1188419-A2 Gingival retraction cords Ultradent Products, Inc. (US) 2002-03-20 EP disclosed
US-6309221-B1 A KIT INCLUDING PROPYLHEXEDRINE AND AT LEAST ONE IN-SITU POLYMERIZABLE MONOMER (PREFERABLY A PHOPHOALKYL ESTER OF METHACRYLIC ACID) CAPABLE OF ADHERING TO DENTIN AND BECOMING A BARRIER TO MICROORGANISMS ULTRADENT PRODUCTS, INC. 2001-10-30 US disclosed
US-6309221-B1 A KIT INCLUDING PROPYLHEXEDRINE AND AT LEAST ONE IN-SITU POLYMERIZABLE MONOMER (PREFERABLY A PHOPHOALKYL ESTER OF METHACRYLIC ACID) CAPABLE OF ADHERING TO DENTIN AND BECOMING A BARRIER TO MICROORGANISMS ULTRADENT PRODUCTS, INC. 2001-10-30 US disclosed
US-5786384-A Agents for the treatment and protection of the skin BEIERSDORF AG (DE) 1998-07-28 US disclosed
US-5652261-A ADMINISTERING VITAMIN E MIXTURE; SUNSCREEN, ANTIINFLAMMATORY, ANTIAGING, AND WOUND HEALING AGENTS BEIERSDORF AG (DE) 1997-07-29 US disclosed
US-5541220-A SKIN DISORDERS, WOUND HEALING AGENTS, ANTIINFLAMMATORY AGENTS AND RADIATION RESISTANCE BEIERSDORF AG (DE) 1996-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129444-A1 Novel weight reduction composition and uses thereof HCRTR1, GPR119, HCRTR2 SIGMAR1 915/4885CTSK 2102/4885MEN1 1985/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.